AZN

AstraZeneca’s Sipavibart shows promising results in COVID-19 prevention trial

AstraZeneca's sipavibart shows promising results in Phase III COVID-19 prevention trial for immunocompromised patients, reducing symptomatic cases significantly. A potential game-changer in protecting vulnerable populations...

May 16, 2024

AstraZeneca plc 6.6% potential upside indicated by Berenberg Bank

AstraZeneca plc with ticker (LON:AZN) now has a potential upside of 6.6% according to Berenberg Bank.Berenberg Bank set a target price of 13,000 GBX for the company, which when compared..

May 9, 2024

AstraZeneca Plc completes equity investment with Cellectis

AstraZeneca plc (LON:AZN) completes equity investment with Cellectis, aiming to develop innovative cell and gene therapy products for various medical needs...

May 7, 2024

AstraZeneca plc -13.2% potential downside indicated by Deutsche

AstraZeneca plc with ticker (LON:AZN) now has a potential downside of -13.2% according to Deutsche.Deutsche set a target price of 10,500 GBX for the company, which when compared to the..

May 3, 2024

AstraZeneca plc -13.0% potential downside indicated by Deutsche

AstraZeneca plc with ticker (LON:AZN) now has a potential downside of -13.0% according to Deutsche.Deutsche set a target price of 10,500 GBX for the company, which when compared to the..

April 26, 2024

AstraZeneca plc -13.0% potential downside indicated by Deutsche

AstraZeneca plc with ticker (LON:AZN) now has a potential downside of -13.0% according to Deutsche.Deutsche set a target price of 10,500 GBX for the company, which when compared to the..

April 26, 2024

AstraZeneca plc 13.8% potential upside indicated by Barclays

AstraZeneca plc with ticker (LON:AZN) now has a potential upside of 13.8% according to Barclays.Barclays set a target price of 12,500 GBX for the company, which when compared to the..

April 12, 2024

AstraZeneca Plc to increase Dividend by 7% for 2024

AstraZeneca plc (LON:AZN) announces a 7% increase in annual dividend for 2024 to $3.10 per share, reflecting confidence in performance and cash generation...

April 11, 2024

AstraZeneca Plc’s Enhertu approved in the US for HER2+ solid tumours

AstraZeneca plc and Daiichi Sankyo's Enhertu has gained US approval for treating HER2-positive solid tumours, marking a significant advancement in cancer treatment...

April 8, 2024

AstraZeneca’s Imfinzi shows positive results in Phase III trial for small cell lung cancer

AstraZeneca's Imfinzi shows significant improvement in overall survival and progression-free survival in limited-stage small cell lung cancer patients after chemoradiotherapy. Exciting breakthrough in treatment...

April 5, 2024

AstraZeneca’s Voydeya approved in the US as add-on therapy for PNH patients with EVH

AstraZeneca's Voydeya (danicopan) has been approved in the US as add-on therapy for PNH patients with EVH. Find out more about this breakthrough treatment...

April 2, 2024

AstraZeneca Ultomiris granted approval in US for treatment of adults with neuromyelitis optica spectrum disorder

Ultomiris, the first long-acting C5 complement inhibitor, shows promise in reducing relapse risk for AQP4 Ab+ NMOSD patients. Learn more here...

March 25, 2024

AstraZeneca expands late-stage rare disease pipeline with Amolyt Pharma acquisition

AstraZeneca plc (LON:AZN) has entered an agreement to acquire Amolyt Pharma, focusing on treatments for rare endocrine diseases, including hypoparathyroidism...

March 14, 2024

AstraZeneca plc -6.2% potential downside indicated by Deutsche

AstraZeneca plc with ticker (LON:AZN) now has a potential downside of -6.2% according to Deutsche.Deutsche set a target price of 9,500 GBX for the company, which when compared to the..

March 7, 2024

AstraZeneca and Daiichi Sankyo’s Dato-DXd validated by EMA for lung and breast cancer treatment

AstraZeneca and Daiichi Sankyo's datopotamab deruxtecan (Dato-DXd) receives EMA validation for lung and breast cancer treatments, advancing the potential for improved patient outcomes...

March 4, 2024

AstraZeneca plc -5.4% potential downside indicated by Deutsche

AstraZeneca plc with ticker (LON:AZN) now has a potential downside of -5.4% according to Deutsche.Deutsche set a target price of 9,500 GBX for the company, which when compared to the..

March 1, 2024

AstraZeneca’s Voydeya recommended for PNH treatment in EU

AstraZeneca's Voydeya for PNH patients is recommended for EU approval. Learn about this promising treatment and its potential benefits for patients...

February 26, 2024

AstraZeneca plc 24.6% potential upside indicated by JP Morgan Cazenove

AstraZeneca plc with ticker (LON:AZN) now has a potential upside of 24.6% according to JP Morgan Cazenove.JP Morgan Cazenove set a target price of 12,500 GBX for the company, which..

February 22, 2024

AstraZeneca’s Tagrisso plus chemotherapy appoved for lung cancer in the US

AstraZeneca's Tagrisso approved in the US for EGFRm non-small cell lung cancer with chemotherapy. FLAURA2 trial results show significant benefit...

February 19, 2024

AstraZeneca reports Strong Growth and Pipeline Momentum in FY and Q4 2023

AstraZeneca reports strong FY and Q4 2023 results, with revenue growth, new medicine approvals, and optimistic growth projections for 2024...

February 8, 2024

News and Interview Alerts

Company Presentations

TEAM Plc’s Mark Clubb reviews 2022 and sets out the Company plans for 2023

Enteq Technologies Investor Presentation 2023

R&Q Insurance Holdings overview, investment case and progress (VIDEO)

TEAM plc poised for future growth (VIDEO)

Q&As

Dr Allan Syms on Cizzle Biotechnology’s CIZ1B US accreditation

22 June 2026

NB Private Equity Partners: Future realisations supported by resilient portfolio growth

15 June 2026

Oriole Resources CEO Martin Rosser highlights resource growth potential at Mbe gold project

15 June 2026

Criterium Energy set for potential gas-led inflection point (TSX:CEQ)

15 June 2026

Cora Gold CEO Bert Monro on Sanankoro drilling campaign and fully funded development plans

15 June 2026

Hardman & Co

Chesnara Plc: Acquisitions show immediate benefits

2 September 2026

Arbuthnot Banking Group Plc 1H’26: accelerating franchise growth

4 August 2026

Real Estate Credit Investments maintains dividend as credit remains resilient

3 August 2026

Real Estate Credit Investments (RECI) FY’26 results: High yield, clear path to dividend cover

13 July 2026

Cavendish plc: Solid performance in still tough markets

30 June 2026

Green News

Ferro-Alloy Resources signs MoU with Maglut for rare earth supply

24 September 2026

Ampeak Energy reports H1 2026 results as AW1 Battery Project advances

23 September 2026

Drax upgrades 2026 EBITDA outlook after strong trading and BSIF acquisition

17 September 2026

Thor Energy receives A$1.3m first deferred payment from Tivan

15 September 2026

View all Sustainable sectors, Plcs and news >>

Search

Latest Interviews

Sintana Energy: Namibia Drilling Window Opens As Chevron, TotalEnergies And Galp Advance The Next Catalysts (video)

Ilika plc: Stereax Revenues Begin as Goliath Finds New Routes Beyond EVs (video)

Firering Strategic Minerals: LimeCo Stake Rises as Kilns 3 and 4 Set Up the Next Growth Test (video)

DynaResource: Higher Revenues, New Veins And A 2026 Push To Unlock San José de Gracia’s Bigger Prize (video)

Manx Financial Group Expands Lending Push with Deposits Up 12% and New Products Incoming (video)

EDX Medical Group: Sir Chris Evans on the Diagnostics Shift That Could Redefine Early Cancer Detection (video)

BrokerTalk

Cora Gold Sanankoro Drilling Programme Highlights Resource Growth Potential, Cavendish

9 June 2026

Finseta FY25 Results Show Investment Year Progress, Shore Capital

9 June 2026

Meridian Holdings Expands Brand Reach and Serbia Presence, Says Zacks

9 June 2026

Global Opportunities Trust Research: Flexible strategy targets real returns and downside protection

3 June 2026

Capricorn Energy Strengthens Momentum Ahead of Egypt Concession Catalyst, Cavendish

28 May 2026

Funds

Premier Miton UK Multi Cap Income Fund: The case for UK income and small-cap stocks

24 September 2026

Structured products fund Volta Finance delivers 0.5% net return in August

24 September 2026

Personal Group praised by Fund Manager for income growth and market share gains

23 September 2026

The Biotech Growth Trust plc – Why Biotech’s Recovery Could Still Have Further to Run (video)

23 September 2026

ACG Metals ‘substantial cash flow’ potential highlighted by Gervais Williams

23 September 2026

View all Funds, Market Insights and news >>

FTSE 100 News

Convatec appoints Jens Viebke as Non-Executive Director

27 August 2026

Smiths Group appoints two independent Non-Executive Directors

25 August 2026

Melrose Industries announces claims programme and GKN Garden Grove restart target

25 August 2026

AstraZeneca strengthens funding position with €2.55 billion Eurobond issue

25 August 2026

UK Broker Ratings

Syncona Limited (SYNC.L) Stock Analysis: Exploring a 71% Potential Upside for Investors

24 September 2026

SSP Group PLC (SSPG.L) Stock Analysis: Navigating a 26.66% Potential Upside Amidst Market Headwinds

24 September 2026

Spire Healthcare Group PLC (SPI.L) Stock Analysis: Navigating Healthcare Growth with a 7.64% Potential Upside

24 September 2026

SOFTCAT PLC (SCT.L) Stock Analysis: A 16.44% Potential Upside in the IT Solutions Market

24 September 2026

DiscoverIE Group PLC (DSCV.L) Stock Analysis: Assessing Growth Potential and Analyst Ratings

24 September 2026

AZN

AstraZeneca’s Sipavibart shows promising results in COVID-19 prevention trial

May 16, 2024

AstraZeneca plc 6.6% potential upside indicated by Berenberg Bank

May 9, 2024

AstraZeneca Plc completes equity investment with Cellectis

AstraZeneca plc (LON:AZN) completes equity investment with Cellectis, aiming to develop innovative cell and gene therapy products for various medical needs...

May 7, 2024

AstraZeneca plc -13.2% potential downside indicated by Deutsche

May 3, 2024

AstraZeneca plc -13.0% potential downside indicated by Deutsche

April 26, 2024

AstraZeneca plc -13.0% potential downside indicated by Deutsche

April 26, 2024

AstraZeneca plc 13.8% potential upside indicated by Barclays

April 12, 2024

AstraZeneca Plc to increase Dividend by 7% for 2024

AstraZeneca plc (LON:AZN) announces a 7% increase in annual dividend for 2024 to $3.10 per share, reflecting confidence in performance and cash generation...

April 11, 2024

AstraZeneca Plc’s Enhertu approved in the US for HER2+ solid tumours

AstraZeneca plc and Daiichi Sankyo's Enhertu has gained US approval for treating HER2-positive solid tumours, marking a significant advancement in cancer treatment...

April 8, 2024

AstraZeneca’s Imfinzi shows positive results in Phase III trial for small cell lung cancer

April 5, 2024

AstraZeneca’s Voydeya approved in the US as add-on therapy for PNH patients with EVH

AstraZeneca's Voydeya (danicopan) has been approved in the US as add-on therapy for PNH patients with EVH. Find out more about this breakthrough treatment...

April 2, 2024

AstraZeneca Ultomiris granted approval in US for treatment of adults with neuromyelitis optica spectrum disorder

Ultomiris, the first long-acting C5 complement inhibitor, shows promise in reducing relapse risk for AQP4 Ab+ NMOSD patients. Learn more here...

March 25, 2024

AstraZeneca expands late-stage rare disease pipeline with Amolyt Pharma acquisition

AstraZeneca plc (LON:AZN) has entered an agreement to acquire Amolyt Pharma, focusing on treatments for rare endocrine diseases, including hypoparathyroidism...

March 14, 2024

AstraZeneca plc -6.2% potential downside indicated by Deutsche

March 7, 2024

AstraZeneca and Daiichi Sankyo’s Dato-DXd validated by EMA for lung and breast cancer treatment

AstraZeneca and Daiichi Sankyo's datopotamab deruxtecan (Dato-DXd) receives EMA validation for lung and breast cancer treatments, advancing the potential for improved patient outcomes...

March 4, 2024

AstraZeneca plc -5.4% potential downside indicated by Deutsche

March 1, 2024

AstraZeneca’s Voydeya recommended for PNH treatment in EU

AstraZeneca's Voydeya for PNH patients is recommended for EU approval. Learn about this promising treatment and its potential benefits for patients...